Novartis is sending 500 jobs to the scrap heap while adding 350 ‘high-tech’ positions for growth
Novartis is taking out the ax again in its ongoing global reorganization, cutting into its R&D group while making room for hundreds of new hires. Following an overhaul that was focused on the US and Asia last year, it’s the Basel campus that’s getting a makeover now.
Up to 500 jobs in Novartis’ drug development, “traditional” manufacturing and coordination group are being scrapped, with the staffers either being laid off, retiring early or moving to other locations. Moving into the company will be 350 new employees for “high-tech” positions in Switzerland, also for drug development as well as “innovative” biologics manufacturing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.